CorMedix Swings to Q3 Profit, Revenue Rises; Lifts Full-Year Guidance

MT Newswires Live11-12

CorMedix (CRMD) reported Q3 earnings Wednesday of $1.26 per diluted share, swinging from a loss of $0.05 a year earlier.

One analyst polled by FactSet expected $0.95.

Revenue for the quarter ended Sept. 30 was $104.3 million, compared with $11.5 million a year earlier. Analysts surveyed by FactSet expected $86 million.

For Q4, the company expects net revenue in the range of $115 million to $135 million. Analysts surveyed by FactSet expect $118.8 million.

CorMedix said it now expects full-year 2025 pro forma net revenue of $390 million to $410 million, compared with the prior estimate of $375 million. Analysts polled by FactSet expect $283.7 million.

CorMedix shares were up more than 6% in recent Wednesday pre-bell activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment